Pacylex Pharmaceuticals Publishes a New Myristoylation Inhibitor Mechanism of Anti-Cancer Activity in Molecular Cancer Therapeutics
Pacylex Pharmaceuticals Publishes a New Myristoylation Inhibitor Mechanism of Anti-Cancer Activity in Molecular Cancer Therapeutics ...
Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors
Ocular Therapeutix's Elutyx drug delivery platform offers sustained long-term effects. See why OCUL stock is a Buy.
Medscape3d
First-line Treatment of Advanced Ovarian Cancer: Current Research and Perspectives
In this review we will focus on antivascular EGF inhibitors, EGF receptor (EGFR)-targeted agents and immunologic stimulators. Phase III trials are currently in progress to determine the role of ...
PharmiWeb1d
Glioblastoma Treatment Drugs Market Set to Reach USD 1,317.4 Million by 2033 at a 5.7% of CAGR
Glioblastoma Treatment Drugs MarketThe glioblastoma treatment drugs market is poised for substantial growth, with a projected valuation of approximately USD 756.1 million in 2023. The market is ...
Medscape2d
Systemic Therapy of Kidney Cancer: Tyrosine Kinase Inhibitors, Antiangiogenesis or IL-2?
§ p = 0.0001 between temsirolimus and IFN-α. ¶ p = 0.0001. # p = 0.0001. ** p = 0.001. NR: Not reported; ORR: Overall response rate; OS: Overall survival; PFS ...
Frontiers6d
New insights in ferroptosis: Potential therapeutic targets for the treatment of ischemic stroke
We further discuss the latest progress in the intervention of ferroptosis as a therapeutic target for ischemic stroke and summarize the research progress and regulatory mechanism of ferroptosis ...
modernretina5d
Diabetic Macular Edema
MK-3000, formally known as EYE103, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wnt signaling pathway.